Other issues that we could not evaluate need more investigation, such as the biomarkers of predictive of response to nimotuzumab, the correct time point for evaluating those biomarkers, and the immune response in ESCC patients, for selecting appropriate patients and exploring more potential mechanisms to enhance anti-EGFR efficacy. The gene discussed is EGFR; the disease is esophageal squamous cell carcinoma.